Benefits
Rapid rise in blood ketones
In crossover studies of healthy adults, MCT oil raised blood ketones (beta-hydroxybutyrate and acetoacetate), most of all with pure C8, peaking 0.5 to 3 hours after a dose taken with breakfast; the response was about twice as high without a meal. In 80 older adults, 30 g/day for 14 days raised ketones without changing cognition. Higher ketones are a blood marker, not proof of more energy.
Self-rated vitality and fatigue scores
In sedentary adults aged 60 to 74 who all walked twice a week for 12 weeks, 2 to 6 g/day of MCT raised SF-36 vitality and general health scores more than a long-chain fat control, in a single trial run by an MCT maker. In 61 adults with rheumatoid arthritis, 30 g/day for 16 weeks improved vitality and fatigue within the MCT group, but neither differed from control at any visit; a food company funded that trial.
Body weight and body fat versus long-chain fats
Replacing long-chain fats with MCT gave a small weight difference in pooled trials: 0.69 kg of body weight, 0.89 kg of body fat and 1.78 cm of waist across 11 trials, and 0.51 kg and 1.46 cm across 13 trials in 749 adults. The evidence was rated low to moderate in quality, commercial bias was detected, and the reviewers called for independent confirmation.
Food intake at a later meal
Pooled across 17 studies in 291 people, MCT moderately reduced how much was eaten at a later laboratory meal compared with long-chain fat, with little effect on hunger ratings or appetite hormones. In one crossover in overweight men, peptide YY and leptin rose more after MCT, but the authors concluded these hormones did not explain the lower intake.
Brain ketone uptake and cognition
In 52 people with mild cognitive impairment, 30 g/day for 6 months raised brain ketone uptake by 230% on imaging. Pooled across 10 studies in people with mild cognitive impairment or Alzheimer's disease, MCT improved general cognition but not memory, language or attention. In healthy older adults, a 14-day trial in 80 people and a 3-month trial in 63 found no significant cognitive change.
Caprylic triglyceride medical food trials
A 90-day trial of the medical food AC-1202 in 152 people with Alzheimer's disease, run by its maker, found a 1.9-point ADAS-Cog difference at day 45 but missed its day-90 primary comparison, with a day-90 difference only in APOE4 non-carriers. A 26-week trial in 413 patients built on that subgroup found no significant difference (0.76 points, p = 0.25).
Endurance exercise performance
Twelve trained runners taking 60 g/day for two weeks showed no significant difference from corn oil in time to exhaustion, VO2max or blood ketones. In eight ultra-endurance cyclists, sprint and time-trial times were slower with MCT plus carbohydrate than with carbohydrate alone, and half the riders had gastrointestinal symptoms.
Effects on Candida yeast in lab cultures
In lab cultures, caprylic acid (C8) and capric acid (C10) blocked Candida albicans from switching to its thread form, sticking to surfaces and forming biofilms. The human data come from hospital feeding studies in preterm infants, one with 12 babies, which do not apply to adults. No trial has tested MCT oil for yeast in adults, and a yeast infection needs medical care.
Mechanism of action
Portal vein absorption bypassing lymphatic transport
Unlike long-chain fats, which are packed into chylomicrons and enter the lymph, medium-chain fats are absorbed without needing bile acids, and C8 and C10 travel mostly as free fatty acids through the portal vein straight to the liver. This is why blood ketones rise within hours of a dose; whether people feel more energetic is a separate question.
Hepatic ketogenesis via mitochondrial beta-oxidation
In the liver, medium-chain fatty acids enter mitochondria largely without the carnitine shuttle that long-chain fats need and are rapidly broken down to acetyl-CoA, which feeds ketone production (beta-hydroxybutyrate and acetoacetate). C8 is the most ketogenic: in a crossover study it was about three times as ketogenic as C10 and six times as ketogenic as C12.
Small, short-lived rise in energy expenditure
In 24 overweight men eating MCT-rich or olive oil diets for 28 days each, energy expenditure ran 0.04 kcal/min higher on MCT at day 2 but the difference was no longer significant by day 28, while upper-body fat fell more on MCT. Any extra calorie burn is small and fades.
Clinical trials
Randomized controlled trial comparing MCT oil (18 to 24 g/day) with olive oil inside a 16-week supervised weight-loss program with weekly group counseling. (St-Onge et al. 2008, Am J Clin Nutr)
49 overweight adults aged 19 to 50 randomized; 31 completed. 16-week intervention.
Endpoint body weight was 1.67 kg lower on MCT oil than on olive oil (P = 0.013). Greater loss of total fat mass (P = 0.071) and trunk fat mass (P = 0.10) only trended in MCT's favor, although endpoint trunk fat, total fat and intra-abdominal fat were each lower on MCT. An adjunct to calorie restriction, not a substitute for it.
Randomized, double-blind, placebo-controlled parallel-group trial of AC-1202 (20 g/day caprylic triglyceride from day 8) vs placebo for 90 days; primary endpoints were ADAS-Cog and ADCS-CGIC at day 90. Accera, Inc., which makes the product, funded and designed the study, and five of the six authors were its employees. (Henderson et al. 2009, Nutr Metab (Lond))
152 adults with mild-to-moderate Alzheimer's disease; 90-day intervention.
Blood beta-hydroxybutyrate rose 2 hours after dosing. On ADAS-Cog, the intention-to-treat group differed from placebo by 1.9 points at day 45, but the day-90 primary comparison was not significant (p = 0.077), and CGIC and MMSE did not differ. Among APOE4 non-carriers (n = 55) a 3.36-point difference remained at day 90. Gastrointestinal adverse events were more frequent on AC-1202. A medical food used under medical supervision, not a retail MCT oil.
Double-blind, placebo-controlled, randomized parallel-group trial (NOURISH AD) stratified by APOE genotype, testing the same caprylic triglyceride as AC-1202; the primary outcome was the 26-week change in ADAS-Cog11 among APOE4 non-carriers. Three of the five authors list Cerecin, Inc. as their affiliation. (Henderson et al. 2020, J Alzheimers Dis)
413 patients with mild-to-moderate Alzheimer's disease; 275 APOE4 non-carriers in the primary analysis.
The primary outcome missed: the ADAS-Cog11 difference was 0.76 points (p = 0.25), and the secondary outcomes detected no drug effect. The authors concluded the formulation failed to improve cognition or functional ability.
Double-blind, randomized, placebo-controlled two-part study: a dose-selection part and a two-period crossover of 30 g/day for 14 days, with cognition and memory-related brain activity tested on day 1 and day 15. (O'Neill et al. 2019, Hum Psychopharmacol)
Healthy older adults; 8 completed the dose-selection part and 80 the crossover.
Peak blood beta-hydroxybutyrate rose, but there was no improvement in cognitive function or memory-related neuronal activity. Diarrhea affected 100% of participants in the dose-selection part and 75% in the crossover, and 11% withdrew because of adverse events.
Randomized, double-blind, placebo-controlled parallel-group trial: 6 g/day of long-chain fat (control), C10-rich MCT, C8-rich MCT, or 2 g MCT plus 4 g long-chain fat, for 12 weeks; every group walked 40 minutes twice a week. Quality of life (SF-36) was a secondary endpoint. Four of the five authors work for MCT maker The Nisshin OilliO Group. (Ishikawa et al. 2023, Front Nutr)
Sedentary adults aged 60 to 74 in Japan with a body mass index under 24.
SF-36 physical functioning, general health and vitality scores, plus one summary score, rose significantly more in all three MCT groups than in the control group, in actual or change scores; the control group did not change on any SF-36 score. Role, bodily pain and physical component summary scores did not differ.
Randomized, double-blind, placebo-controlled crossover: 60 g/day MCT oil or 56 g/day corn oil for 2 weeks each, followed by a maximal treadmill test and a run to exhaustion. (Misell et al. 2001, J Sports Med Phys Fitness)
12 trained male endurance runners, mean age 30.5.
Time to exhaustion (99.8 vs 106.5 minutes) and VO2max did not differ between MCT and corn oil, nor did lactate, glucose, beta-hydroxybutyrate, free fatty acids or triglycerides. The authors concluded MCT neither enhances endurance nor alters performance-related metabolism in trained runners.